新穎馬利乳酸桿菌APS1及其用途

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

104125376

專利證號

I 559925

專利獲證名稱

新穎馬利乳酸桿菌APS1及其用途

專利所屬機關 (申請機關)

國立臺灣大學

獲證日期

2016/12/01

技術說明

1. 一種用於延緩體脂肪生成與改善糖尿病血糖偏高症狀之組合物，其包含有效劑量之馬利乳酸桿菌(Lactobacillus mali) APS1，並使用可食性材料作為載劑形成組合物。組合物之形式可進一步包含其他益生菌物種如乳桿菌屬(lactobacillus sp. )、雙叉乳桿菌屬(Bifidobacterium sp. )、鏈球菌屬物種(Streptococcus sp. ) 、酵母菌(yeasts)或與腸球菌屬(Enterococcus sp.)及桿菌屬(Bacillus sp.)製成飼料添加物。 2. 第 1項所述之乳酸桿菌，具有可降低及改善攝取高熱量飲食的族群，具有初期第二型糖尿病特徵，包括體脂肪生成堆積、血液中高總膽固醇濃度、高LDL/HDL比例、葡萄糖耐受性異常、血糖偏高、高胰島素及低Glucagon-like peptide-1濃度等症狀。 Results indicated that the Lb. mali APS1 could altered metabolism in mice model, including significantly loss of bodyweight gain and increase body lean/fat ratio than when compared with high fat diet positive control. Further, oOral administration of Lb. mali APS1 also showed a better functional properties on glucose homeostasis regulation in oral glucose tolerance test (OGTT) and area under curve (AUC) test. Additionally, Lb. mali APS1 could reduce abdominal and epididymal fat accumulation in three dimensional X-ray photographs measured by Micro-CT System. Above all, the information obtained in this study provide evidences for concideringconsidering Lb. mali APS1 as a therapeutic agent to protect human or animal modulate obese-relative metabolic syndrome.

備註

連絡單位 (專責單位/部門名稱)

產學合作總中心

連絡電話

33669945

網址